⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12126628 | 0.96 | — | — | |
| SCHEMBL6125031 | 0.87 | — | — | |
| SCHEMBL10211377 | 0.69 | — | — | |
| SCHEMBL12402136 | 0.67 | — | — | |
| Formaldehyde SCHEMBL28108132 | 0.67 | — | — | |
| Formaldehyde SCHEMBL27975443 | 0.67 | — | — | |
| SCHEMBL10121150 | 0.65 | — | — | |
| SCHEMBL6652099 | 0.64 | — | — | |
| SCHEMBL7937518 | 0.64 | — | — | |
| SCHEMBL12874231 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-20170258790-A1 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | US | disclosed |
| EP-3214076-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK ACTIVATING EFFECT | Shionogi & Co., Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-3187498-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING EFFECT | Shionogi & Co., Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9670222-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-9663469-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170096691-A1 | SELECTIVE ADVANTAGE IN FERMENTATION | NOVOGY, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170008896-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-12 | — | — | US | disclosed |
| US-20160318870-A1 | RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160215274-A1 | MICROORGANISMS ENGINEERED TO USE UNCONVENTIONAL SOURCES OF PHOSPHOROUS OR SULFUR | GINKGO BIOWORKS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20130274264-A1 | PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-17 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130045964-A1 | MANDELAMIDE HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-21 | — | — | US | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| WO-2012065981-A1 | COMPOUND OR MIXTURE OF PHOTOLUMINESCENT COMPOUNDS | ENI S.P.A. (IT) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122834-A1 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20110263549-A1 | 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2009061676-A2 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |